IDEAYA Biosciences, Inc.

IDYA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017
Operating Activities
Net Income $-11.9M
Depreciation & Amortization $391.0K
Depreciation —
Amortization —
Stock-Based Compensation $136.0K
Net Cash from Operating Activities $-12.2M
Investing Activities
Capital Expenditures $1.8M
Business Acquisitions —
Net Cash from Investing Activities $-8.9M
Financing Activities
Dividends Paid —
Stock Repurchases —
Net Cash from Financing Activities $17.5M
Net Change in Cash $-3.7M
Free Cash Flow $-14.0M
← Newer Page 2 of 2 Older →